natgillin/translations-raw huggingface dataset:
5 (5 x 1) vials (multipack)
5 (5 x 1) vial
5 (5 x 1) vials (multipack)
5 (5 x 1) vial (multiplo pakiranje)
5 (5 x 1) vials (multipack)
5 (5 x 1) vial (skupno pakiranja)
5 (5 x 1) vials (multipack)
5 (5 x 1) viala (večje pakiranje)
5 (5x1) bags (multipack)
5 (5x1) vreč (skupno pakiranje)
5 (5x1) bottles (multi-pack)
5 (5x1) plastenke (skupno pakiranje)
5 (5x1) bottles (multipack)
5 (5x1) plastenk (skupno pakiranje)
5 (5x1) pre-filled syringe (multipack)
5 (5 x 1) napolnjena brizga (skupno pakiranje)
5 (conditional)
5 (pogojno)
5 - Take the 21-gauge needle out of its wrapping and place it firmly onto the tip (nozzle) of the syringe.
5 - Odstranite ovojnino z igle velikosti 21 in jo čvrsto pritrdite na konico (nastavek) brizge.
5 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration.
5 Opravljena je bila kumulativna analiza neželenih učinkov zlomov kosti iz randomiziranih, s primerjalnim zdravilom kontroliranih, dvojno slepih kliničnih preskušanj pri več kot 8100 bolnikih, zdravljenih s pioglitazonom, in 7400 bolnikih, ki so prejemali primerjalna zdravila, v obdobju do 3,5 leta.
5 ampoules per cane
5 ampul na niz
5 ampoules per cane
5 ampul na vrsto
5 ampoules, each containing 2,000 or 4,000 doses of cell suspension (attached to the cane is a coloured clip displaying the dose; 2,000 doses: salmon-pink coloured clip, and 4,000 doses: yellow coloured clip).
5 ampul, vsaka vsebuje 2.000 or 4.000 odmerkov suspenzije celic, na nizu je barvna priponka, ki kaže odmerek (2.000 odmerkov: lososovo rožnata priponka, 4.000 odmerkov: rumena priponka)
5 As initial combination with metformin, myalgia is reported as uncommon.
5pri začetnem kombiniranem zdravljenju z metforminom so o mialgiji poročali občasno
5 Based on Normal approximation
5 Na osnovi normalne aproksimacije
5 bottles + 5 dosage
5 plastenk + 5 odmernih
5 bottles + 5 x 5 ml syringes
5 plastenk + 5 x 5 ml brizg
5 cartridges
10 vložkov
5 cartridges
3 vložki
5 cartridges
5 injekcijskih vložkov
5 cartridges
5 vložkov
5 cartridges
uporaba
5 cartridges 10 cartridges
5 vložkov 10 vložkov
5 cartridges for SurePal 10 10 cartridges for SurePal 10
5 vložkov za injekcijski peresnik SurePal 10 10 vložkov za injekcijski peresnik SurePal 10
5 cartridges for SurePal 15 10 cartridges for SurePal 15
5 vložkov za injekcijski peresnik SurePal 15 10 vložkov za injekcijski peresnik SurePal 15
5 cartridges of 1 ml solvent
5 vložkov z 1 ml vehikla
5 cartridges of 3 mL.
5 vložkov po 3 ml.
5 cartridges of 3 ml.
vložkov s 3 ml.
5 cartridges of 3ml.
vložki s 3 ml.
5 Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.4).
5 Med zdravljenjem z duloksetinom ali kmalu po prekinitvi zdravljenja so poročali o primerih samomorilnih misli in samomorilnega vedenja (glejte poglavje 4.4).
5 centimetres around the navel (belly button).
Za to je priporočeno mesto na sprednjem delu stegen.
5 D-63303 Dreieich Germany
5 D-63303 Dreieich Nemčija
5 days
5 dni.
5 days (horses) Milk: 5 days (cattle)
5 dni (konji) mleko: 5 dni (goveda)
5 days (horses, pigs)
5 dni (konji, prašiči) Mleko:
5 days (pigs)
5 dni (prašiči)
5 days (pigs)
5 dni (prašiči) mleko: 5 dni
5 days.
5 dni
5 doses
5 od- merkov
5 doses (10 ml)
5 odmerkov (10 ml)
5 doses (10 ml)
5 odmerkov (10ml)
5 doses (10 ml) 10 doses (20 ml) 25 doses (50 ml) 50 doses (100 ml) 4 x 5 doses (10 ml)
5 odmerkov (10 ml) 10 odmerkov (20 ml) 25 odmerkov (50 ml) 50 odmerkov (100 ml) 4 x 5 odmerkov (10 ml)
5 doses (10 ml) 25 doses (50 ml)
5 odmerkov (10 ml) 25 odmerkov (50 ml)
5 doses for gilts and sows, 20 doses for piglets
5 odmerkov za mladice in svinje, 20 odmerkov za pujske
5 dosing syringes are included in each carton of Kaletra oral solution.
Vsaki škatli peroralne raztopine zdravila Kaletra je priloženih 5 odmernih brizg.
5 dosing syringes are included in the 5 bottle carton of Norvir oral solution Ask your pharmacist for instructions on how to use the syringe correctly.
5 odmernih brizg je priloženih v škatli s 5 plastenkami Norvir peroralne raztopine Za navodilo o pravilni uporabi brizge prosite farmacevta.
5 g NexoBrid powder in 50 g gel is applied to a burn wound area of 250 cm2.
Zdravilo 5 g NexoBrid prašek in 50 g gel se nanese na predel opeklinske rane površine 250 cm2.
5 g NexoBrid powder in 50 g gel is applied to a burn wound area of 250 cm2.
Zdravilo NexoBrid 5 g praška v 50 g gela se nanese na predel opeklinske rane površine 250 cm2.
5 g, 10 g 15 g TUBE
5 g, 10 g IN 15 g TUBA
5 g, 10 g and 15 g aluminium tubes with a plastic screw cap.
5 g, 10 g in 15 g aluminijaste tube s plastično navojno zaporko.
5 hard capsules
5 trdih kapsul
5 How Amyvid is stored
5 Shranjevanje zdravila Amyvid
5 How Scintimun is stored
5 Shranjevanje zdravila Scintimun
5 How to store ABILIFY oral solution
Shranjevanje zdravila ABILIFY peroralna raztopina
5 How to store ABILIFY orodispersible tablets
Shranjevanje zdravila ABILIFY orodisperzibilne tablete
5 How to store ABILIFY tablets
Shranjevanje zdravila ABILIFY tablete
5 How to store ACOMPLIA
5 Shranjevanje zdravila ACOMPLIA
5 How to store ADCIRCA
Shranjevanje zdravila ADCIRCA
5 How to store ADENURIC
5 Shranjevanje zdravila ADENURIC
5 How to store ADROVANCE
Shranjevanje zdravila ADROVANCE
5 How to store Aripiprazole Accord
Shranjevanje zdravila Aripiprazol Accord
5 How to store Avaglim
Shranjevanje zdravila Avaglim
5 How to store Avandamet
Shranjevanje zdravila Avandamet
5 How to store Avandia
Shranjevanje zdravila Avandia
5 How to store Bondronat
5 Shranjevanje zdravila Bondronat
5 How to store Busilvex
Shranjevanje zdravila Busilvex
5 How to store Busulfan Fresenius Kabi
Shranjevanje zdravila Busulfan Fresenius Kabi
5 How to store Caelyx
Shranjevanje zdravila Caelyx
5 How to store Carbaglu
5 Shranjevanje zdravila Carbaglu
5 How to store Cetrotide
Shranjevanje zdravila Cetrotide
5 How to store CIALIS
Shranjevanje zdravila CIALIS
5 How to store Clopidogrel/Acetylsalicylic acid Zentiva
Shranjevanje zdravila Klopidogrel/acetilsalicilna kislina Zentiva
5 How to store Competact
5 Shranjevanje zdravila Competact
5 How to store Corbilta
5 Shranjevanje zdravila Corbilta
5 How to store Cystadane
5 Shranjevanje zdravila Cystadane
5 How to store Diacomit
5 Shranjevanje zdravila Diacomit
5 How to store Dukoral
Shranjevanje zdravila Dukoral
5 How to store DULOXETINE BOEHRINGER INGELHEIM
5 Shranjevanje zdravila DULOKSETIN BOEHRINGER INGELHEIM
5 How to store DuoPlavin
Shranjevanje zdravila DuoPlavin
5 How to store Elaprase
Shranjevanje zdravila Elaprase
5 How to store Esbriet
Shranjevanje zdravila Esbriet
5 How to store EVICEL
5 Shranjevanje zdravila EVICEL
5 How to store EXUBERA
5 Shranjevanje zdravila EXUBERA
5 How to store FORSTEO
Shranjevanje zdravila FORSTEO
5 How to store FOSAVANCE
Shranjevanje zdravila FOSAVANCE
5 How to store GANFORT
Shranjevanje zdravila GANFORT
5 How to store GANFORT single-dose
Shranjevanje zdravila GANFORT (enoodmerna oblika)
5 How to store Glubrava
5 Shranjevanje zdravila Glubrava
5 How to store Helicobacter Test INFAI
Shranjevanje zdravila Test Helicobacter INFAI
5 How to store Helicobacter Test INFAI
Shranjevanje zdravilo Test Helicobacter INFAI
5 How to store Helicobacter Test INFAI for children of the age 3-11
Shranjevanje zdravila Test Helicobacter INFAI za otroke od 3 do 11 let
5 How to store Humira
5 Shranjevanje zdravila Humira
5 How to store Ivabradine Anpharm
Shranjevanje zdravila Ivabradine Anpharm
5 How to store Levodopa/Carbidopa/Entacapone Orion
5 Shranjevanje zdravila Levodopa/Carbidopa/Entacapone Orion
5 How to store Metalyse
5 Shranjevanje zdravila Metalyse
5 How to store MULTAQ
5 Shranjevanje zdravila MULTAQ
5 How to store Onsenal
Shranjevanje zdravila Onsenal
5 How to store Opgenra.
5 Shranjevanje zdravila Opgenra
5 How to store ORENCIA
5 Shranjevanje zdravila ORENCIA
5 How to store Osigraft
Shranjevanje zdravila Osigraft
5 How to store Paxene
Shranjevanje zdravila Paxene
5 How to store PhotoBarr
Shranjevanje zdravila PhotoBarr
5 How to store Preotact
5 Shranjevanje zdravila Preotact
5 How to store Procoralan
Shranjevanje zdravila Procoralan
5 How to store Raptiva
Shranjevanje zdravila Raptiva
5 How to store ReFacto AF
Shranjevanje zdravila ReFacto AF
5 How to store Refludan
5 Shranjevanje zdravila Refludan
5 How to store Revatio
5 Shranjevanje zdravila Revatio
5 How to store Revestive
Shranjevanje zdravila Revestive
5 How to store Savene
5 Shranjevanje zdravila Savene
5 How to store Siklos
5 Shranjevanje zdravila Siklos
5 How to store Stalevo
5 Shranjevanje zdravila Stalevo
5 How to store Suboxone
5 Shranjevanje zdravila Suboxone
5 How to store TESAVEL
Shranjevanje zdravila TESAVEL
5 How to store Thymanax
Shranjevanje zdravila Thymanax
5 How to store Trudexa
5 Shranjevanje zdravila Trudexa
5 How to store Valdoxan
Shranjevanje zdravila Valdoxan
5 How to store VANTAVO
Shranjevanje zdravila VANTAVO
5 How to store Vedrop
Shranjevanje zdravila Vedrop
5 How to store Vidaza
5 Shranjevanje zdravila Vidaza
5 How to store Wilzin
5 Shranjevanje zdravila Wilzin
5 How to store Xyrem
5 Shranjevanje zdravila Xyrem
5 How to store YTRACIS
5 Shranjevanje zdravila YTRACIS
5 How to store ZIMULTI
5 Shranjevanje zdravila ZIMULTI
5 implants
5 implantatov
5 implants preloaded in implanters + 1 actuator
5 implantantov, napolnjenih v implantatorje + 1 aktuator
5 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2–3 kg over one year.
5 V kontroliranih preskušanjih s primerjalnim zdravilom je bilo povprečno povečanje telesne mase pri pioglitazonu, dajanemu kot monoterapija, 2–3 kg v enem letu.
5 Includes Dry skin, Skin chapped
5 zajema suho kožo, razpokano kožo
5 Includes Pruritus, Pruritus generalised
5 zajema pruritus, generalizirani pruritus
5 Including increased alanine aminotransferase [ALT], aspartate aminotransferase [AST] and bilirubin.
5 Vključno z zvišano alanin-aminotransferazo [ALT], aspartat-aminotransferazo [AST] in bilirubinom.
5 Infusion-related back and chest pain, which may radiate to other areas, including, but not limited to, the pelvis, shoulder girdle or rib cage.
5 Z infundiranjem povezana bolečina v križu in prsih, ki lahko seva v druge predele, med drugim v medenico, ramenski obroč ali prsni koš.
5 inhalers (monthly multipack)
5 inhalatorjev (mesečno skupno pakiranje)
5 intraruminal devices
5 intrarumi nalnih sistemov
5 log-rank test (stratified)
5 Test log-rang (stratificirani)
5 matrices of 3.0 x 2.5 cm
5 matriksov 3,0 x 2,5 cm
5 mcg
5 mikrogram ov
5 Mean adjusted for baseline DBP, baseline HbA1c, baseline eGFR, geographical region and number of antihypertensive medicinal products
5 Povprečje, prilagojeno za vrednost diastoličnega krvnega tlaka ob izhodišču, vrednost HbA1c ob izhodišču, vrednost eGFR ob izhodišču, geografsko regijo in število antihipertenzivnih zdravil
5 Mean HbA1c change is the difference between the saxagliptin 5 mg + metformin and metformin alone groups.
5 Povprečna sprememba HbA1c je razlika med skupinama s kombinacijo 5 mg saksagliptina in metforminom ter z metforminom samim.
5 mg (15 IU)
5 mg (15 i.e.)
5 mg (250 KIU)
5 mg (250 k.i.e.)
5 mg (see section 4.4).
5 mg (glejte poglavje
5 mg / 850 mg
dovoljenja za promet
5 mg benazepril hydrochloride & 40 mg spironolactone
5 mg benazeprilijev hidroklorid & 40 mg spironolakton
5 mg film-coated tablets are pink, biconvex, round.
5 mg filmsko obložene tablete so rožnate, na obeh straneh izbočene, okrogle.
5 mg film-coated tablets: Each film-coated tablet contains 0.47 mg lactose monohydrate.
5 mg fimsko obložene tablete: Ena filmsko obložena tableta vsebuje 0,47 mg laktoze monohidrata.
5 mg fondaparinux sodium in 0.4 ml solution for injection
5 mg natrijevega fondaparinuksa v 0,4 ml raztopine za injiciranje.
5 mg fondaparinux sodium in 0.4 ml solution for injection
5 mg natrijevega fondaparinuksata v 0,4 ml raztopine za injiciranje.
5 mg of sodium benzoate.
5 mg natrijevega benzoata
5 mg of white to almost white powder in a glass vial closed with a rubber stopper and a cap
5 mg belega do skoraj belega praška v stekleni viali, zaprti z gumijastim zamaškom in zaporko
5 mg once a day
5 mg enkrat na dan
5 mg once daily (days 1-21 of repeated 28-day cycles)
5 mg enkrat na dan (od 1. do 21. dne, v ponavljajočih se 28-dnevnih ciklih)
5 mg once daily on days 1-21, every 28 days
5 mg enkrat na dan od 1. do 21. dne, vsakih 28 dni
5 mg per meal
5 mg na obrok
5 mg single dose
enkraten odmerek 5 mg
5 mg single dose
Posamezen odmerek 5 mg
5 mg tablet: AK 10 mg tablet: BE 20 mg tablet: CD 40 mg tablet: BCK
5 mg tableta: AK 10 mg tableta: BE 20 mg tableta: CD 40 mg tableta: BCK
5 mg tablets are available in pack sizes of 14, 28, 56, or 98 film-coated tablets in non-perforated blisters, 14, 28, 56, or 98 film-coated tablets in non-perforated calendar blisters and 30x1 or 90x1 film-coated tablets in perforated unit dose blisters.
5 mg tablete so na voljo v pakiranjih po 14, 28, 56 ali 98 filmsko obloženih tablet v neperforiranih pretisnih omotih, 14, 28, 56 ali 98 filmsko obloženih tablet v neperforiranih koledarskih pretisnih omotih ter 30x1 ali 90x1 filmsko obloženih tablet v perforiranih pretisnih omotih za enkratni odmerek.
5 mg twice daily
5 mg dvakrat na dan
5 mg) or iron oxide red (E172) (for 10 mg and 30 mg) or iron oxide yellow (E172) (for 15 mg).
172) (za 10 mg and 30 mg), rumen železov oksid (E 172) (za 15 mg).
5 mg/ Pump actuation
5 mg/ pritisk
5 mg/ pump actuation
5 mg/pritisk
5 mg/kg
infliximab 5 mg/kg
5 mg/kg body weight
5 mg/kg telesne mase
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
mg/kg, dano v obliki intravenske infuzije, potem pa dodatne infuzije odmerkov 5 mg/kg 2 in tednov po prvi infuziji, potem pa na vsakih 8 tednov.
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
Odmerek je 5 mg/kg v intravenski infuziji, čemur naj sledita dodatni infuziji z odmerkoma 5 mg/kg 2 in 6 tednov po prvi infuziji, potem pa na vsakih 8 tednov.
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
Odmerek je 5 mg/kg v obliki intravenske infuzije, čemur naj sledita dva dodatna infuzijska odmerka po 5 mg/kg v 2. in 6. tednu po prvi infuziji, potem pa zdravilo infundirajte bolniku na vsakih 8 tednov.
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
Odmerek je 5 mg/kg v obliki intravenske infuzije, čemur naj sledita dve infuziji v odmerku 5 mg/kg 2 in 6 tednov po prvi infuziji, potem pa na vsakih 8 tednov.
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusions at 2 and 6 weeks after the first infusion.
Intravenski infuziji 5 mg/kg naj sledita dodatni infuziji 5 mg/kg 2 in 6 tednov po prvi infuziji.
5 mg/kg given as an intravenous infusion followed by an additional 5 mg/kg infusion 2 weeks after the first infusion.
Odmerek je 5 mg/kg v intravenski infuziji, temu pa naj sledita še dodatni infuziji zdravila v odmerku 5 mg/kg v 2. tednu po prvi infuziji.
5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.
Ena je za vzdrževalno zdravljenje prejemala infliksimab v odmerku 5 mg/kg na vsakih 8 tednov, druga pa na vsakih 12 tednov.
5 mg/kg intravenous
5 mg/kg intravensko
5 mg/kg IV 30-90 min
5 mg/kg i.v.
5 mg/kg once every 24 hours
5 mg/kg vsakih 24 ur
5 mg/pump
5 mg/pritisk
5 micrograms Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.25 milligram Al+)
5 mikrogramov adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,25 miligrama Al+)
5 micrograms Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.25 milligram Al+)
5 mikrogramov, adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,25 miligrama Al+)
5 million
5 milijonov
5 million IU/0.5 ml
5 milijonov i.e./0,5 ml
5 million IU/0.5 ml solution for injection 1 single dose vial
5 milijonov i.e./0,5 ml raztopina za injiciranje 1 viala z enkratnim odmerkom
5 million IU/0.5mL
5 milijonov
5 million IU/ml
5 milijonov
5 million IU/ml
5 milijonov i.e./ml
5 million IU/ml powder and solvent for solution for injection
5 milijonov i.e./ml prašek in vehikel za raztopino za injiciranje
5 ml
5 vial
5 ml (10 doses)
5 ml (10 odmerki)
5 ml (100 IU/ml)
5 ml (100 i.e./ml)
5 ml (100 mg) twice daily
5 ml (100 mg) dvakrat na dan
5 ml (200 IU/ml)
5 ml (200 i.e./ml)
5 ml (400 IU/ml)
5 ml (400 i.e./ml)
5 ml (40U/ml)
5 ml (40 e/ml)
5 ml (50 IU/ml)
5 ml (50 i.e./ml)
5 ml (600 IU/ml)
5 ml (600 i.e./ml)
5 ml (one 5 ml vial)
5 ml (ena 5 ml viala)
5 ml colourless type 1 glass vial with grey bromobutyl rubber stopper sealed with brown colour flip-off with aluminium seal.
5-mililitrska viala iz prozornega stekla tipa 1 s sivim brombutilnim zamaškom in rjavo aluminijasto zaporko.
5 ml concentrate in a clear glass vial with chlorobutyl/butyl Flurotec stopper and aluminium cap with plastic flip-off cap.
5 ml koncentrata v stekleni, prozorni viali s sivim zamaškom iz klorobutil/butil Flurotec in aluminijasto zaporko z modro plastično snemno zaporko.
5 ml concentrate in a plastic vial with chlorobutyl/butyl Flurotec stopper and aluminium cap with plastic flip-off cap.
5 ml koncentrata v plastični viali s sivim zamaškom iz klorobutil/butil Flurotec in aluminijasto zaporko z modro plastično snemno zaporko.
5 ml glass vial (type I) closed by a polytetrafluoroethylene grey chlorobutyl rubber stopper or an uncoated grey bromobutyl rubber stopper and sealed with an aluminium/polypropylene flip cap.
Koncentrat zdravila Keppra je na voljo v 5 ml stekleni viali (tip I), ki je zaprta s sivim klorbutilnim gumijastim zamaškom prevlečenim s politetrafluoroetilenom ali z neprevlečenim sivim brombutilnim gumijastim zamaškom in zapečatena z aluminijasto/polipropilensko zaporko (flip).
5 ml glass vial (type I) with bromobutyl stoppers and sealed with an aluminium flip off cap.
Koncentrat zdravila Matever je na voljo v 5 ml steklenih vialah (tip I) s bromobutilnega zamaški in zapečatene z aluminijasto zaporko (flip off).
5 mL of concentrate for solution for infusion.
5 ml koncentrata za raztopino za infundiranje.
5 ml of Norvir solution (for antiretroviral purposes) contains 1.7 g of alcohol and 1.3 g propylene glycol.
5 ml zdravila Norvir (za namene protiretrovirusnega zdravljenja) vsebuje 1,7 g alkohola in 1,3 g propilenglikola.
5 ml of suspension in a vial (type I glass) for 10 doses with a plunger stopper (rubber butyl) – pack size of 1.
5 ml suspenzije v viali (steklo tipa I) za 10 odmerkov s potopnim zamaškom (butilna guma) – velikost pakiranja 1.
5 ml of the reconstituted suspension contain 1 g of mycophenolate mofetil.
5 ml pripravljene suspenzije vsebuje 1 g mofetilmikofenolata.
5 mL sodium chloride and water for injections.
5 ml natrijevega klorida in vode za injekcije
5 ml solution in a vial (type I glass) with stopper (rubber) and a seal (aluminium) with flip-off cap.
5 ml raztopine v viali (iz stekla vrste I) z zamaškom (guma) in pokrovčkom (aluminij) z zaporko, ki se odtrga na poteg (flip-off).
5 mL solvent in a type 1 glass pre-filled syringe with a bromobutyl rubber plunger stopper
5 ml vehikla v napolnjeni injekcijski brizgi iz stekla tipa 1 z zamaškom z batom iz brombutilne gume
5 mL Solvent in pre-filled syringe
5 ml vehikla v napolnjeni injekcijski brizgi
5 ml Starter Pack 1 x 25 ml bottle.
5 ml začetno pakiranje 1 x 25 ml steklenica
5 ml suspension contains 1 g mycophenolate mofetil when reconstituted.
5 ml pripravljene suspenzije vsebuje 1 g mofetilmikofenolata.
5 ml suspension in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
5 ml suspenzija v viali (iz brezbarvnega stekla tipa 1) s prirobljenozaporko (iz aluminija), z zamaškom (iz klorobutilne gume (tipa 1)) in spokrovčkom, ki se odtrga (iz polipropilena).
5 ml VIAL
5-MILILITRSKA VIALA
5 ml vial (type 1 clear glass) with a stopper (chlorobutyl rubber), seal (aluminium) and a flip-off cap (polypropylene).
5 ml viala (iz prozornega stekla tipa 1) z zamaškom (iz klorobutilne gume), zaporo (iz aluminija) in snemno zaporko (iz polipropilena).
5 ml vial (type I glass) with a stopper (fluoro-resin coated butyl rubber), one piece seal and blue flip- off cap.
5-mililitrska viala (steklo vrste I) z zamaškom (butilna guma, obložena s fluorovo smolo), enodelno tesnilo in modra zaporka „flip-off“.
5 ml vial Zinc chloride Metacresol Glycerol
5 ml viala: Cinkov klorid Metakrezol Glicerol
5 ml vials to obtain a concentration of 75 mg atosiban in 100 ml.
37,5 mg/5 ml koncentrat za raztopino za infundiranje iz dveh 5 ml vial, da dobite koncentracijo 75 mg atosibana na 100 ml.
5 ml, 15 ml and 30 ml bottle label
5 ml, 15 ml in 30 ml steklenička
5 months after primary vaccination course with ProteqFlu-Te.
5 mesecev po primarnem cepljenju s Proteqflu TE.
5 months after primary vaccination course with ProteqFlu-Te.
5 mesecev po primarnem cepljenju.
5 months for VZIG).
5 mesecev pri VZIG).
5 Most of the reported cases of cardiac failure were associated with fluid retention.
5 Večina opisanih primerov srčnega popuščanja je bila povezana z zastajanjem tekočine.
5 MU presentation :
Jakost 5 ME:
5 multidose
5 večodmernih vsebnikov
5 multidose containers (4 x 0.5 ml doses per containers) 10 multidose containers (4 x 0.5 ml doses per containers) 25 multidose containers (4 x 0.5 ml doses per containers) 50 multidose containers (4 x 0.5 ml doses per containers)
5 večodmernih vsebnikov (4 x 0,5 ml odmerek na vsebnik) 10 večodmernih vsebnikov (4 x 0,5 ml odmerek na vsebnik) 25 večodmernih vsebnikov (4 x 0,5 ml odmerek na vsebnik) 50 večodmernih vsebnikov (4 x 0,5 ml odmerek na vsebnik)
5 n = 432 and 442, for telbivudine and lamivudine groups, respectively.
5 n = 432 za telbivudin in n = 442 za lamivudin.
5 nuclear medicine physicians resulted in a majority read sensitivity of 92% (95% CI: 78-98%) and specificity of 100% (95% CI: 80-100%).
78-98 %) in specifičnost 100 % (95-odstotni IZ: 80-100 %).
5 Observed during use in acute tibia fractures
5Opaženo med uporabo pri akutnih zlomih golenice
5 Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high (≥ 2.26 mmol/l).
5Učinek so opazili pri normalnih izhodiščnih vrednostih na tešče (< 1,69 mmol/l), ki so se povečale (≥ 2,26 mmol/).
5 Oedema or fluid retention was reported in 13.2% of patients on bosentan and 10.9% of patients on placebo.
5 O edemu ali zastajanju tekočine so poročali pri 13,2 % bolnikov na bosentanu in pri 10,9 % bolnikov na placebu.
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 O edemih so poročali pri 6–9% bolnikov, zdravljenih s pioglitazonom leto dni v kontroliranih kliničnih preskušanjih.
5 Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 O edemih so poročali pri 6 do 9 % bolnikov, ki so v kontroliranih kliničnih preskušanjih prejemali pioglitazon več kot eno leto.
5 Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 O edemih so poročali pri 6-9 % bolnikov, zdravljenih s pioglitazonom leto dni v kontroliranih kliničnih preskušanjih.
5 Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 O edemih so poročali pri 6–9 % bolnikov, zdravljenih s pioglitazonom leto dni v kontroliranih kliničnih preskušanjih.
5 OJ No L 143 of 27.06.95
5UL št L 143 z dne 27.06.95
5 OJ No.
5 OJ št.
5 Only patients who were in MMR at a specific time point are included as responders for that time point.
5 Kot odzivni bolniki ob določeni časovni točki so šteti samo bolniki, pri katerih je prišlo do glavnega molekularnega odziva ob tej časovni točki.
5 or equivalent antigenic quantity determined by a suitable immunochemical method.
5 ali enakovredna količina antigenov, določena z ustrezno imunokemijsko metodo.